The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus

Antiviral Therapy

Volumn 10, Issue 6, 2005, Pages 769-776

  Lebray, Pascal ^a,b   Nalpas, Bertrand ^a,b   Vallet Pichard, Anaïs ^a,b   Broissand, Christine ^a   Sobesky, Rodolphe ^a,b   Serpaggi, Jeanne ^a,b   Fontaine, Hélèn ^a,b   Pol, Stanislas ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NEUTROPENIA; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 25444466243     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M & Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Hadziyannis SJ & Papatheodoridis GV. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opinion on Pharmacotherapy 2003; 4:541-551.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J & Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347:975-982.
4. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
5. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clinical Infectious Diseases 2003; 37(Suppl 4):315-322.
6. Dieterich DT & Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clinical Infectious Diseases 2003; 37:533-541.
7. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A & Ferenci P. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123:141-151.
8. Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ & Wright HI. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42:907-912.
9. Lunel-Fabiani F, Fouchard-Hubert I & Gergely AE. [Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C]. Pathologie-biologie (Paris) 2003; 51:520-524.
10. Gergely AE, Lafarge P, Fouchard-Hubert I & Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002; 35:1281-1282.
11. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302-1311.
12. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ & Sulkowski MS. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. The American Journal of Gastroenterology 2003; 98:2491-2499.
13. Wright HI, Gavaler JS, Baddpur N & Van Thiel DH. Granulocyte colony stimulating factor (G-CSF) combined with alpha-interferon for the treatment of liver allograft recipients with viral hepatitis. Journal of Hepatology 1994; 21:915-916.
14. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S & Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines, Cellular & Molecular Therapy 2000; 6:149-154.
15. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Reviews in Gastroenterological Disorders 2004; 4(Suppl 1):S31-38.
16. Crippin JS, McCashland T, Terrault N, Sheiner P & Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation 2002; 8:350-355.
17. Van Vlierbergh H, Delanghe JR, De Vos M & Leroux-Roel G. Factors influencing ribavirin-induced hemolysis. Journal of Hepatology 2001; 34:911-916.
18. ain AB, Eghtesad B, Venkataramanan R, Fontes PA, Kashyap R, Dvorchik I, Shakil AO, Kingery L & Fung JJ. dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transplantation 2002; 8:1007-1013.
19. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, Liang TJ & Hoofnagle JH. Neutropaenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36:1273-1279.
20. Renou C, Harafa A, Cummins C, Muller P, Demattei C, Jouve E, Bertrand JJ & Halfon P. Threshold for neutropaenia in the adjustment of interferon treatment in HCV infection. Hepatology 2003; 37:949-950; author reply 950.
21. Renou C, Harafa A, Bouabdallah R, Demattei C, Cummins C, Rifflet H, Muller P, Ville E, Bertrand J, Benderitter T & Halfon P. Severe neutropaenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary? The American Journal of Gastroenterology 2002; 97:1260-1263.
22. Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T, Unuma T, Okano K, Ikeda Y, Hirano M, Kawase T, Takano S, Matsumoto K, Ohashi Y & Omata M. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999; 29:1573-1580.
23. Farrell G, Cooksley WG, Dudley FJ & Watson K. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group. Journal of Viral Hepatitis 1997; 4:317-323.
24. Everson GT, Jensen DM, Craig JR, van Leeuwen DJ, Bain VG, Ehrinpreis MN, Albert D, Joh T & Witt K. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 1999; 30:271-276.
25. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, Bargallo X, Garcia-Criado A, de Lazzari E, Larrousse M, Leon A, Lonca M, Milinkovic A, Gatell JM & Mallolas J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-36.
26. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine 2004; 351:438-450.
27. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D & Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS 2004; 18:75-79.
28. Moreno L, Quereda C, Moreno A, Perez-Elias MJ, Antela A, Casado JL, Dronda F, Mateos ML, Barcena R & Moreno S. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18:67-73.
29. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, Pedreira J, Barreiro P, Garcia-Samaniego J, Martin-Carbonero L, Jimenez-Nacher I & Soriano V. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028.
30. Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A & Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clinical Transplantation 2004; 18:166-173.
31. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J & Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77:190-194.
32. Mukherjee S, Rogge J, Weaver L & Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplantation Proceedings 2003; 35:3042-3044.